Biogen Q3 2025 Earnings Report

Biogen EPS Results

• Actual EPS: N/A
• Consensus EPS: $3.89
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Biogen Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.34 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Biogen Announcement Details

• Quarter: Q3 2025
• Date: 10/29/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, October 30, 2025
• Conference Call Time: 8:30AM ET

Biogen (NASDAQ:BIIB) is a biotechnology company focused on the discovery, development and delivery of therapies for neurological, autoimmune and rare diseases. The company’s marketed portfolio includes multiple sclerosis treatments such as Avonex, Tysabri (developed in collaboration with Elan Pharmaceuticals) and Tecfidera, as well as Spinraza for spinal muscular atrophy. In addition to its established products, Biogen offers Vumerity and Fampyra to address the needs of patients with various neurodegenerative and neuromuscular conditions.

Beyond its commercial portfolio, Biogen maintains an active research and development pipeline targeting Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and other central nervous system disorders. The company has pursued innovative modalities including antisense oligonucleotides and monoclonal antibodies, often entering strategic partnerships to advance late-stage clinical candidates. Biogen’s commitment to neuroscience research is supported by collaborations with academic institutions and biotechnology firms around the world.

Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen operates in key biopharmaceutical markets across North America, Europe, Japan and emerging regions. The company’s global infrastructure encompasses research facilities, manufacturing sites and commercial offices, enabling it to serve patients and healthcare providers in more than 90 countries. Led by an executive management team with deep industry expertise, Biogen continues to invest in science-driven innovation aimed at transforming the standard of care for neurological and rare disease patients.